Efficacy of food supplement to improve metabolic syndrome parameters in patients affected by moderate to severe psoriasis during anti-TNFα treatment.
OBJECTIVE
Psoriasis is a systemic inflammatory immune-mediated skin disease. Recently a relationship with metabolic syndrome in terms of psoriasis severity and response to therapy was observed.


METHODS
We performed an open-label randomized controlled study to evaluate the role of a nutraceutical containing Q10 coenzyme, Krill-oil, lipoic acid, resveratrol, Vitis vinifera seed oil, vitamin E and selenium in addition to etanercept therapy for patients affected by psoriasis and metabolic syndrome. Forty patients were enrolled and divided into two arms, one receiving only etanercept, one other receiving also the neutraceutical. After a period of 3 months (T1) a second evaluation of the considered parameters was performed.


RESULTS
At T1 statistically significant differences were detected in HDL cholesterol and triglycerides values both comparing the two arms and in the nutraceutical arm.


CONCLUSIONS
Our results show that the dietary addiction of the nutraceutical to the etanercept therapy in patients affected by both psoriasis and metabolic syndrome could help to restore the normal lipid profile.
Department of Dermatology "Daniele Innocenzi" Sapienza University of Rome, Polo Pontino, Rome, Italy - concetta.potenza@uniroma1.it.
N
N
Skroza
I
I
Proietti
N
N
Bernardini
G
G
La Viola
F
F
Nicolucci
R
R
Pampena
E
E
Tolino
S
S
Zuber
M T
MT
Mancini
V
V
Soccodato
V
V
Balduzzi
C
C
Potenza
D000328:Adult; D000818:Animals; D000975:Antioxidants / Q000008:administration & dosage; D015415:Biomarkers / Q000097:blood; D015992:Body Mass Index; D008076:Cholesterol, HDL / Q000097:blood; D004042:Dietary Fats, Unsaturated / Q000008:administration & dosage; D019587:Dietary Supplements; D000068800:Etanercept; D033201:Euphausiacea; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D024821:Metabolic Syndrome / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D008875:Middle Aged; D011565:Psoriasis / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D000077185:Resveratrol; D012639:Seeds; D012643:Selenium / Q000008:administration & dosage; D012720:Severity of Illness Index; D013267:Stilbenes / Q000008:administration & dosage; D008063:Thioctic Acid / Q000008:administration & dosage; D016896:Treatment Outcome; D014280:Triglycerides / Q000097:blood; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D014451:Ubiquinone / Q000008:administration & dosage / Q000031:analogs & derivatives; D014810:Vitamin E / Q000008:administration & dosage; D027843:Vitis
D000975:Antioxidants; D015415:Biomarkers; D008076:Cholesterol, HDL; D004042:Dietary Fats, Unsaturated; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D018124:Receptors, Tumor Necrosis Factor; D013267:Stilbenes; D014280:Triglycerides; D014409:Tumor Necrosis Factor-alpha; D014451:Ubiquinone; D014810:Vitamin E; D008063:Thioctic Acid; C024989:coenzyme Q10; D012643:Selenium; D000068800:Etanercept; D000077185:Resveratrol